Abstract
The search for biomarkers to aid in the diagnosis and prognosis of psychiatric conditions and predict response to treatment is a focus of twenty-first century medicine. The current lack of biomarkers in routine use is attributable in part to the existing way mental health conditions are diagnosed, being based upon descriptions of symptoms rather than causal biological evidence. New ways of conceptualizing mental health disorders together with the enormous advances in genetic, epidemiological, and neuroscience research are informing the brain circuits and physiological mechanisms underpinning behavioural constructs that cut across current diagnostic DSM-5 categories. Combining these advances with ‘Big Data’, analytical approaches offer new opportunities for biomarker development. Here we provide an introductory perspective to this volume, highlighting methodological strategies for biomarker identification; ranging from stem cells, immune mechanisms, genomics, imaging, network science to cognition. Thereafter we emphasize key points made by contributors on affective disorders, psychosis, schizophrenia, and autism spectrum disorder. An underlying theme is how preclinical and clinical research are informing biomarker development and the importance of forward and reverse translation approaches. In considering the exploitation of biomarkers we note that there is a timely opportunity to improve clinical trial design informed by patient ‘biological’ and ‘psychological’ phenotype. This has the potential to reinvigorate drug development and clinical trials in psychiatry. In conclusion, we are poised to move from the descriptive and discovery phase to one where biomarker panels can be evaluated in real-life cohorts. This will necessitate resources for large-scale collaborative efforts worldwide. Ultimately this will lead to new interventions and personalized medicines and transform our ability to prevent illness onset and treat complex psychiatric disorders more effectively.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Andrews DS, Marquand A, Ecker C, McAlonan G (2018) Using pattern classification to identify brain imaging markers in autism spectrum disorder. https://doi.org/10.1007/7854_2018_47
Battaglia M, Khan WU (2018) Reappraising preclinical models of separation anxiety disorder, panic disorder, and CO2 sensitivity: implications for methodology and translation into new treatments. https://doi.org/10.1007/7854_2018_42
Herron JW, Nerurkar L, Cavanagh J (2018) Neuroimmune biomarkers in mental illness. https://doi.org/10.1007/7854_2018_45
Hunter SA, Lawrie SM (2018) Imaging and genetic biomarkers predicting transition to psychosis. https://doi.org/10.1007/7854_2018_46
Johnstone M, Hillary RF, St Clair D (2018) Stem cells to inform the neurobiology of mental illness. https://doi.org/10.1007/7854_2018_57
Kalia M, Costa E, Silva J (2015) Biomarkers of psychiatric diseases: current status and future prospects. Metab Clin Exp. https://doi.org/10.1016/j.metabol.2014.10.026
Lydon-Staley DM, Bassett DS (2018) Network neuroscience: a framework for developing biomarkers in psychiatry. https://doi.org/10.1007/7854_2018_41
MacQueen DA, Young JW, Cope ZA (2018) Cognitive phenotypes for biomarker identification in mental illness: forward and reverse translation. https://doi.org/10.1007/7854_2018_50
Maron E, Lan C-C, Nutt D (2018) Imaging and genetic approaches to inform biomarkers for anxiety disorders, obsessive–compulsive disorders, and PSTD. https://doi.org/10.1007/7854_2018_49
Notter T (2018) Immunological processes in schizophrenia pathology: potential biomarkers? https://doi.org/10.1007/7854_2018_43
Prata D, Mechelli A, Kapur S (2014) Clinically meaningful biomarkers for psychosis: a systematic and quantitative review. Neurosci Biobehav Rev 45:134–141. https://doi.org/10.1016/j.neubiorev.2014.05.010
Pratt JA, Morris BJ, Dawson N (2018) Deconstructing schizophrenia: advances in preclinical models for biomarker identification. https://doi.org/10.1007/7854_2018_48
Reddaway JT, Doherty JL, Lancaster T, Linden DE, Walters J, Hall J (2018) Genomic and imaging biomarkers in schizophrenia. https://doi.org/10.1007/7854_2018_52
Scarr E et al (2015) Biomarkers for psychiatry: the journey from fantasy to fact, a report of the 2013 CINP think tank. Int J Neuropsychopharmacol 18(10):pyv042. https://doi.org/10.1093/ijnp/pyv042
Slaney C, Hinchcliffe JK, Robinson ESJ (2018) Translational shifts in preclinical models of depression: implications for biomarkers for improved treatments. https://doi.org/10.1007/7854_2018_44
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Pratt, J., Hall, J. (2018). Biomarkers in Neuropsychiatry: A Prospect for the Twenty-First Century?. In: Pratt, J., Hall, J. (eds) Biomarkers in Psychiatry. Current Topics in Behavioral Neurosciences, vol 40. Springer, Cham. https://doi.org/10.1007/7854_2018_58
Download citation
DOI: https://doi.org/10.1007/7854_2018_58
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-99641-7
Online ISBN: 978-3-319-99642-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)